Suzhou Auzone Biological Technology Co., Ltd.

The main purpose of the study is to study the pharmacokinetic characteristics of TTYP01 tablets (specification: 30 mg, produced by Wuxi Hequan Pharmaceutical Co., Ltd. commissioned by Suzhou Aozong Biotechnology Co., Ltd.) in healthy participants under different dietary conditions, and to evaluate the effect of food on the bioavailability of TTYP01 tablets. Secondary purpose of the study: to study the safety of TTYP01 tablets in healthy participants.

Main purpose: TTYP01 tablets (specification: 30 mg) developed by Suzhou Aozong Biotechnology Co., Ltd. were used as the test drug. Two administration methods were used under fasting conditions: the first method was to take the drug orally directly with water, and the second method was to dissolve the drug in sufficient water before taking it orally. The pharmacokinetic differences between the two administration methods in vivo were compared, and the relative bioavailability of the test drug after oral administration by different administration methods was evaluated. Secondary purpose: To evaluate the safety and tolerability of oral administration of TTYP01 tablets by the above two administration methods in Chinese healthy subjects under fasting conditions.

To explore the difference in efficacy between 14-day and 28-day courses of TTYP01 tablets in the treatment of acute ischemic stroke.